A combined tumor burden–based nomogram for synchronous esophageal and gastric cancers: development and external validation - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A novel nomogram utilizing tumor burden for assessing synchronous esophageal and gastric cancers: creation and external validation

  • By

  • Meng Xie

  • Jing Wang

  • Ziyu Jia

  • Ke Ji

  • Qi Wu

  • September 4, 2026

Share

  • 1

    A prognostic nomogram for synchronous esophageal and gastric cancers (SEGC) was developed using a Combined EG_Stage framework.

  • 2

    The study included a development cohort of 46 patients and an external validation cohort of 88 patients from the SEER database.

  • 3

    Key predictors in the nomogram were age, treatment modality, and Combined EG_Stage, with overall survival as the primary endpoint.

  • 4

    The external validation showed a C-index of 0.681 and significant differences in median overall survival based on risk stratification.

  • 5

    The model is considered hypothesis-generating due to modest discrimination and limited sample size, necessitating further multicenter validation.

Original Source(s)

A combined tumor burden–based nomogram for synchronous esophageal and gastric cancers: development and external validation

  • by Meng Xie, Jing Wang, Ziyu Jia, Ke Ji, Qi Wu

  • September 4, 2026

Related Content

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Toward Precision Cardio-Oncology in Breast Radiotherapy

Correction: Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer